Nasdaq · CIK 0001842295
MAZE Maze Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $27.11 on Oct 9, 2026, +21% from the 52-week low and -48% from the high.
Last 90 days
Net insider value
-$4.3M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
10
$4.3M by 4 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
MAZEOct 9, 2026 · close 27.11
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Maze Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Harold Bernstein President, R&D & CMO sell | $435k 16,141 shares | -100% | +19% from low-49% from high | |
| 64Notable | Jason Coloma V Chief Executive Officer sell | $932k 34,501 shares | -190% | +19% from low-49% from high | |
| 12Weak | Atul Dandekar CSBO sell | $203k 7,500 shares | -19% | +21% from low-48% from high | |
| 48Moderate | Harold Bernstein President, R&D & CMO sell | $255k 9,705 shares | -100% | - | |
| 68Notable | Harold Bernstein President, R&D & CMO sell | $270k 10,295 shares | -51% | - | |
| 69Notable | Jason Coloma V Chief Executive Officer sell | $594k 22,638 shares | -45% | - | |
| 50Moderate | Phillips Courtney GC and Corp. Secretary sell | $105k 3,993 shares | -36% | - | |
| 46Moderate | Atul Dandekar CSBO sell | $169k 6,434 shares | -17% | - | |
| 37Weak | Harold Bernstein President, R&D & CMO sell | $426k 16,141 shares | -100% | - | |
| 49Moderate | Jason Coloma V Chief Executive Officer sell | $907k 34,501 shares | -166% | - | |
| 34Weak | Amy Bachrodt SVP, Finance sell | $606k 15,000 shares | -65% | +436% from low-5% from high | |
| 45Moderate | Harold Bernstein President, R&D & CMO sell | $1.8M 45,000 shares | -100% | +436% from low-5% from high | |
| 40Moderate | Atul Dandekar CSBO sell | $2.9M 72,500 shares | -87% | +436% from low-5% from high | |
| 52Moderate | Richard H Scheller director sell | $464k 20,744 shares | -100% | +207% from low-6% from high |
Transactions
The last 95 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stockindirect: The Coloma 2021 Irrevocable Trust10b5-1 | -2,593 | $27.02 | $70k | 15,558 | 10 d ago |
| Oct 1, 2026 | Harold Bernstein President, R&D & CMO | MOption exercise Common Stock10b5-1 | +16,141 | $10.42 | $168k | 16,141 | 10 d ago |
| Oct 1, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock10b5-1 | -16,141 | $26.93 | $435k | 0 | 10 d ago |
| Oct 1, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stockindirect: Coloma Family Trust10b5-1 | -31,908 | $27.02 | $862k | 191,447 | 10 d ago |
| Oct 1, 2026 | Harold Bernstein President, R&D & CMO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,141 | $0.00 | $0 | 144,521 | 10 d ago |
| Sep 29, 2026 | Atul Dandekar CSBO | MOption exercise Common Stock10b5-1 | +7,500 | $10.42 | $78k | 39,816 | 11 d ago |
| Sep 29, 2026 | Atul Dandekar CSBO | SOpen-market sale Common Stock10b5-1 | -7,500 | $27.06 | $203k | 32,316 | 11 d ago |
| Sep 29, 2026 | Atul Dandekar CSBO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 6,643 | 11 d ago |
| Sep 4, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock10b5-1 | -9,705 | $26.22 | $255k | 0 | 34 d ago |
| Sep 2, 2026 | Atul Dandekar CSBO | SOpen-market sale Common Stock | -2,800 | $26.38 | $74k | 35,950 | 38 d ago |
| Sep 2, 2026 | Phillips Courtney GC and Corp. Secretary | SOpen-market sale Common Stock | -1,738 | $26.38 | $46k | 9,262 | 38 d ago |
| Sep 2, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stock | -9,852 | $26.38 | $260k | 40,148 | 38 d ago |
| Sep 2, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock | -4,481 | $26.38 | $118k | 15,519 | 38 d ago |
| Sep 2, 2026 | Phillips Courtney GC and Corp. Secretary | SOpen-market sale Common Stock | -243 | $27.12 | $6,590 | 9,019 | 38 d ago |
| Sep 2, 2026 | Atul Dandekar CSBO | SOpen-market sale Common Stock | -391 | $27.12 | $11k | 35,559 | 38 d ago |
| Sep 2, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stock | -1,375 | $27.12 | $37k | 38,773 | 38 d ago |
| Sep 2, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock | -625 | $27.12 | $17k | 14,894 | 38 d ago |
| Sep 3, 2026 | Atul Dandekar CSBO | SOpen-market sale Common Stock | -3,207 | $26.01 | $83k | 32,352 | 38 d ago |
| Sep 3, 2026 | Phillips Courtney GC and Corp. Secretary | SOpen-market sale Common Stock | -1,990 | $26.01 | $52k | 7,029 | 38 d ago |
| Sep 3, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock | -5,130 | $26.01 | $133k | 9,764 | 38 d ago |
| Sep 3, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stock | -11,282 | $26.01 | $293k | 27,491 | 38 d ago |
| Sep 3, 2026 | Phillips Courtney GC and Corp. Secretary | SOpen-market sale Common Stock | -22 | $25.78 | $567 | 7,007 | 38 d ago |
| Sep 3, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stock | -129 | $25.77 | $3,325 | 27,362 | 38 d ago |
| Sep 3, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock | -59 | $25.78 | $1,521 | 9,705 | 38 d ago |
| Sep 3, 2026 | Atul Dandekar CSBO | SOpen-market sale Common Stock | -36 | $25.81 | $929 | 32,316 | 38 d ago |
| Sep 1, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stockindirect: The Coloma 2021 Irrevocable Trust10b5-1 | -2,593 | $26.31 | $68k | 18,151 | 39 d ago |
| Sep 1, 2026 | Atul Dandekar CSBO | MOption exercise Common Stock | +12,500 | $0.00 | $0 | 38,750 | 39 d ago |
| Sep 1, 2026 | Phillips Courtney GC and Corp. Secretary | MOption exercise Common Stock | +11,000 | $0.00 | $0 | 11,000 | 39 d ago |
| Sep 1, 2026 | Harold Bernstein President, R&D & CMO | MOption exercise Common Stock10b5-1 | +16,141 | $10.42 | $168k | 16,141 | 39 d ago |
| Sep 1, 2026 | Jason Coloma V Chief Executive Officer | SOpen-market sale Common Stockindirect: Coloma Family Trust10b5-1 | -31,908 | $26.29 | $839k | 223,355 | 39 d ago |
| Sep 1, 2026 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock10b5-1 | -16,141 | $26.36 | $426k | 0 | 39 d ago |
| Sep 1, 2026 | Phillips Courtney GC and Corp. Secretary | MOption exercise Restricted Stock Unitsderivative | -11,000 | $0.00 | $0 | 11,000 | 39 d ago |
| Sep 1, 2026 | Atul Dandekar CSBO | MOption exercise Restricted Stock Unitsderivative | -12,500 | $0.00 | $0 | 12,500 | 39 d ago |
| Sep 1, 2026 | Harold Bernstein President, R&D & CMO | MOption exercise Common Stock10b5-1 | +20,000 | $0.00 | $0 | 20,000 | 39 d ago |
| Sep 1, 2026 | Jason Coloma V Chief Executive Officer | MOption exercise Common Stock10b5-1 | +50,000 | $0.00 | $0 | 50,000 | 39 d ago |
| Sep 1, 2026 | Harold Bernstein President, R&D & CMO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,141 | $0.00 | $0 | 160,662 | 39 d ago |
| Sep 1, 2026 | Jason Coloma V Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -50,000 | $0.00 | $0 | 50,000 | 39 d ago |
| Sep 1, 2026 | Harold Bernstein President, R&D & CMO | MOption exercise Restricted Stock Unitsderivative10b5-1 | -20,000 | $0.00 | $0 | 20,000 | 39 d ago |
| Dec 29, 2025 | Atul Dandekar CSBO | MOption exercise Common Stock10b5-1 | +72,400 | $10.42 | $754k | 82,903 | Dec 31, 2025 |
| Dec 29, 2025 | Harold Bernstein President, R&D & CMO | MOption exercise Common Stock10b5-1 | +45,000 | $10.42 | $469k | 45,000 | Dec 31, 2025 |
| Dec 29, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Common Stock10b5-1 | +124 | $10.42 | $1,292 | 13,089 | Dec 31, 2025 |
| Dec 29, 2025 | Atul Dandekar CSBO | SOpen-market sale Common Stock10b5-1 | -66,365 | $40.51 | $2.7M | 16,538 | Dec 31, 2025 |
| Dec 29, 2025 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock10b5-1 | -27,800 | $40.34 | $1.1M | 17,200 | Dec 31, 2025 |
| Dec 29, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Common Stock10b5-1 | +9,876 | $10.42 | $103k | 22,965 | Dec 31, 2025 |
| Dec 29, 2025 | Amy Bachrodt SVP, Finance | SOpen-market sale Common Stock10b5-1 | -9,400 | $40.54 | $381k | 13,565 | Dec 31, 2025 |
| Dec 29, 2025 | Atul Dandekar CSBO | SOpen-market sale Common Stock10b5-1 | -6,035 | $41.13 | $248k | 10,503 | Dec 31, 2025 |
| Dec 29, 2025 | Harold Bernstein President, R&D & CMO | SOpen-market sale Common Stock10b5-1 | -17,200 | $40.93 | $704k | 0 | Dec 31, 2025 |
| Dec 30, 2025 | Atul Dandekar CSBO | MOption exercise Common Stock10b5-1 | +100 | $10.42 | $1,042 | 10,603 | Dec 31, 2025 |
| Dec 29, 2025 | Amy Bachrodt SVP, Finance | SOpen-market sale Common Stock10b5-1 | -600 | $41.16 | $25k | 12,965 | Dec 31, 2025 |
| Dec 29, 2025 | Harold Bernstein President, R&D & CMO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -45,000 | $0.00 | $0 | 342,407 | Dec 31, 2025 |
| Dec 30, 2025 | Atul Dandekar CSBO | SOpen-market sale Common Stock10b5-1 | -100 | $40.36 | $4,036 | 10,503 | Dec 31, 2025 |
| Dec 30, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Common Stock10b5-1 | +2,395 | $10.42 | $25k | 15,360 | Dec 31, 2025 |
| Dec 29, 2025 | Atul Dandekar CSBO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -72,400 | $0.00 | $0 | 74,243 | Dec 31, 2025 |
| Dec 30, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Common Stock10b5-1 | +2,605 | $10.42 | $27k | 17,965 | Dec 31, 2025 |
| Dec 30, 2025 | Atul Dandekar CSBO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100 | $0.00 | $0 | 74,143 | Dec 31, 2025 |
| Dec 30, 2025 | Amy Bachrodt SVP, Finance | SOpen-market sale Common Stock10b5-1 | -5,000 | $40.08 | $200k | 12,965 | Dec 31, 2025 |
| Dec 29, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -124 | $0.00 | $0 | 2,396 | Dec 31, 2025 |
| Dec 29, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,876 | $0.00 | $0 | 23,834 | Dec 31, 2025 |
| Dec 30, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,395 | $0.00 | $0 | 1 | Dec 31, 2025 |
| Dec 30, 2025 | Amy Bachrodt SVP, Finance | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,605 | $0.00 | $0 | 2,581 | Dec 31, 2025 |
| Nov 19, 2025 | Charles J Homcy director | JOther Common Stock | +1,489 | $0.00 | $0 | 31,113 | Nov 21, 2025 |
| Nov 4, 2025 | Third Rock Ventures IV, L.P. owner | JOther Common Stock | -1,600,000 | - | - | 4,473,958 | Nov 5, 2025 |
| Oct 23, 2025 | Charles J Homcy director | GGift Common Stock | -28,423 | $0.00 | $0 | 29,624 | Oct 27, 2025 |
| Oct 6, 2025 | Herve Hoppenot director | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Oct 7, 2025 |
| Sep 22, 2025 | Catherine A. Sohn director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Daniel K Spiegelman director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Richard H Scheller director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Jonathan E Lim director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Sekar Kathiresan director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Atul Dandekar CSBO | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Sep 24, 2025 |
| Sep 22, 2025 | Charles J Homcy director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Phillips Courtney GC and Corp. Secretary | AGrant or award Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 22,000 | Sep 24, 2025 |
| Sep 22, 2025 | Jason Coloma V Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 24, 2025 |
| Sep 22, 2025 | Harold Bernstein President, R&D & CMO | AGrant or award Restricted Stock Unitsderivative | +40,000 | $0.00 | $0 | 40,000 | Sep 24, 2025 |
| Sep 22, 2025 | Amy Bachrodt SVP, Finance | AGrant or award Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 22,000 | Sep 24, 2025 |
| Sep 22, 2025 | Nancy C Andrews director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 22, 2025 | Neil Exter director | AGrant or award Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Sep 24, 2025 |
| Sep 15, 2025 | Richard H Scheller director | SOpen-market sale Common Stock | -20,744 | $22.37 | $464k | 0 | Sep 16, 2025 |
| Sep 2, 2025 | Misbah Tahir Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Sep 2, 2025 |
| Aug 17, 2025 | Neil Exter director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Aug 19, 2025 |
| Feb 3, 2025 | Charles J Homcy director | CConversion Common Stock | +8,807 | - | - | 37,330 | Feb 4, 2025 |
| Feb 3, 2025 | Charles J Homcy director | CConversion Common Stock | +20,717 | - | - | 58,047 | Feb 4, 2025 |
| Feb 3, 2025 | Charles J Homcy director | CConversion Common Stockindirect: By Trust | +7,422 | - | - | 7,422 | Feb 4, 2025 |
| Feb 3, 2025 | Charles J Homcy director | CConversion Series B Preferred Stockderivative | -72,727 | - | - | 0 | Feb 4, 2025 |
| Feb 3, 2025 | Charles J Homcy director | CConversion Series C Preferred Stockderivative | -169,405 | - | - | 0 | Feb 4, 2025 |
| Feb 3, 2025 | Charles J Homcy director | CConversion Series D-1 Preferred Stockderivativeindirect: By Trust | -71,564 | - | - | 0 | Feb 4, 2025 |
| Nov 26, 2024 | Charles J Homcy director | CConversion Series D-1 Preferred Stockderivativeindirect: By Trust | +71,564 | - | - | 7,422 | Feb 4, 2025 |
| Nov 26, 2024 | Charles J Homcy director | CConversion 8% Convertible Note due 2026derivativeindirect: By Trust | - | $78,961.64 | - | - | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | AGrant or award Stock Option (Right to Buy)derivative | +80,385 | $0.00 | $0 | 80,385 | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,385 | - | - | 0 | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | AGrant or award Stock Option (Right to Buy)derivative | +5,704 | $0.00 | $0 | 5,704 | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,704 | - | - | 0 | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | AGrant or award Stock Option (Right to Buy)derivative | +46,675 | $0.00 | $0 | 46,675 | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | DDisposition to issuer Stock Option (Right to Buy)derivative | -46,675 | - | - | 0 | Feb 4, 2025 |
| Dec 9, 2024 | Charles J Homcy director | AGrant or award Stock Option (Right to Buy)derivative | +45,638 | $0.00 | $0 | 45,638 | Feb 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Nancy C Andrewsdirector
- Amy BachrodtSVP, Finance
- Harold BernsteinPresident, R&D & CMO
- Jason Coloma VChief Executive Officer
- Phillips CourtneyGC and Corp. Secretary
- Atul DandekarCSBO
- Neil Exterdirector
- Charles J Homcydirector
- Herve Hoppenotceo, chair, officer, director, other
- Sekar Kathiresanceo, officer, director
- Jonathan E Limceo, chair, officer, director, owner
- Richard H Schellerdirector
- Daniel K Spiegelmandirector
- Catherine A. Sohndirector
- Misbah TahirChief Financial Officer
- Third Rock Ventures IV, L.P.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.